How expressing gratitude improves my life with chronic illness

KYV-101 granted orphan drug status for MG in Europe

The European Medicines Agency granted orphan drug status to the experimental cell therapy KYV-101 to treat myasthenia gravis (MG). The designation is given to medicines that aim to treat life-threatening or chronic debilitating conditions affecting no more than five in every 10,000 people. It provides companies with several…

My twin with MG doesn’t want people to pity him

Author Jane Austen once wrote, “Those who do not complain are never pitied.” I was a mediocre English major in college. I won’t tell you I adored “Pride and Prejudice,” but I’ve always remembered that gut-wrenching line. To pity someone is to feel sorrow, compassion, and sadness due to their…

Soliris eases AChR+ refractory myasthenia gravis disease severity

Soliris (eculizumab) effectively eased disease severity and reduced the need for immunosuppressive therapies in people with treatment-resistant generalized myasthenia gravis with anti-AChR antibodies, a real-world study in Italy shows. The treatment also reduced the number of disease exacerbations that required rescue therapy, such as intravenous immunoglobulin (IVIG)…

Intensive treatment most needed early in MG course: Study

Many adults with myasthenia gravis (MG) need intensive treatment in the first year after diagnosis, with younger patients and women facing a higher risk of death as the disease progresses, a study found. The researchers said the results point to a need for better treatment options. The study, “…